Generic Name and Formulations:
Phentermine HCl 15mg (equivalent to 12mg phentermine), 30mg (equivalent to 24mg phentermine); powder-filled or pellet-filled caps.
Various generic manufacturers
Indications for Phentermine:
A short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥30kg/m2, or ≥27kg/m2 in the presence of other risk factors (eg, hypertension, diabetes, hyperlipidemia).
>16yrs: Individualize. Usual dose: 15–30mg at approx. 2hrs after breakfast.
≤16yrs: not recommended.
Advanced arteriosclerosis. Cardiovascular disease. Moderate to severe hypertension. Hyperthyroidism. Glaucoma. Agitated states. History of drug abuse. During or within 14 days of MAOIs.
Increased risk of primary pulmonary hypertension, valvular heart disease. Discontinue if unexplained dyspnea, angina, syncope, or lower extremity edema develops. Mild hypertension. Diabetes. Prescribe minimal supply to avoid overdose. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. Hypertensive crisis possible with MAOIs. Concomitant weight loss drugs, including SSRIs (fluoxetine, sertraline, fluvoxamine, paroxetine): not recommended. Caution with alcohol. Insulin requirements may be altered. May decrease hypotensive effect of guanethidine.
Primary pulmonary hypertension, regurgitant cardiac valvular disease, palpitation, tachycardia, elevated blood pressure, overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache, dry mouth, unpleasant taste, GI upset, constipation, urticaria, impotence, changes in libido, tolerance (discontinue when occurs); rare: psychotic episodes.
Formerly known under the brand name Fastin.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds